[go: up one dir, main page]

WO2003063892A1 - Utilisation d'apeline - Google Patents

Utilisation d'apeline Download PDF

Info

Publication number
WO2003063892A1
WO2003063892A1 PCT/JP2003/000790 JP0300790W WO03063892A1 WO 2003063892 A1 WO2003063892 A1 WO 2003063892A1 JP 0300790 W JP0300790 W JP 0300790W WO 03063892 A1 WO03063892 A1 WO 03063892A1
Authority
WO
WIPO (PCT)
Prior art keywords
apelin
controllers
secretion
amides
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/000790
Other languages
English (en)
Japanese (ja)
Inventor
Hirokazu Matsumoto
Jiro Noguchi
Shuji Hinuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of WO2003063892A1 publication Critical patent/WO2003063892A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Apeline, ses modifications, ses amides, ses esters ou ses sels utiles en tant que contrôleurs de sécrétion d'hormone adrénocorticotrope ou contrôleurs de sécrétion d'oxytocine.
PCT/JP2003/000790 2002-01-29 2003-01-28 Utilisation d'apeline Ceased WO2003063892A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-020031 2002-01-29
JP2002020031 2002-01-29

Publications (1)

Publication Number Publication Date
WO2003063892A1 true WO2003063892A1 (fr) 2003-08-07

Family

ID=27654317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/000790 Ceased WO2003063892A1 (fr) 2002-01-29 2003-01-28 Utilisation d'apeline

Country Status (1)

Country Link
WO (1) WO2003063892A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
WO2015165936A1 (fr) * 2014-04-29 2015-11-05 University Of Ulster Analogues de l'apeline
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US10005829B2 (en) 2012-11-20 2018-06-26 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033976A1 (fr) * 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, son procede de production et son utilisation
WO2000018793A1 (fr) * 1998-09-25 2000-04-06 Takeda Chemical Industries, Ltd. Derive de peptide
WO2001070769A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derive peptidique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033976A1 (fr) * 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, son procede de production et son utilisation
WO2000018793A1 (fr) * 1998-09-25 2000-04-06 Takeda Chemical Industries, Ltd. Derive de peptide
WO2001070769A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derive peptidique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAZUHITO TATEMOTO ET AL.: "Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICTIONS, vol. 251, 1998, pages 471 - 476, XP002947594 *
LEE DENNIS K. ET AL.: "Characterization of apelin, the ligand for APJ receptor", JOURNAL OF NEUROCHEMISTRY, vol. 74, 2000, pages 34 - 41, XP002225252 *
SHAHRAD TAHERI ET AL.: "The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 291, 2002, pages 1208 - 1212, XP002967758 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US9067971B2 (en) 2012-01-27 2015-06-30 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US9982017B2 (en) 2012-01-27 2018-05-29 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
US10005829B2 (en) 2012-11-20 2018-06-26 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US9683019B2 (en) 2013-07-25 2017-06-20 Novartis Ag Cyclic polypeptides for the treatment of heart failure
WO2015165936A1 (fr) * 2014-04-29 2015-11-05 University Of Ulster Analogues de l'apeline
CN106661089A (zh) * 2014-04-29 2017-05-10 阿尔斯特大学 爱帕琳类似物
US10118954B2 (en) 2014-04-29 2018-11-06 Univeristy Of Ulster Apelin analogues

Similar Documents

Publication Publication Date Title
PL369396A1 (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
PL375344A1 (en) Novel carboxamide compounds having an mch-antagonistic effect, medicaments containing said compounds, and methods for the production thereof
IL173204A0 (en) Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
AU2003267408A1 (en) Flying device
TWI350638B (en) Synchronous rectification switching regulator, control circuit thereof, and method of controlling the operation thereof
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
AU2003254957A1 (en) Controller
AU2003255952A1 (en) Oxytocin inhibitors
ZA200410410B (en) New etonogestrel esters.
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003207445A1 (en) Csf physiologic controller
AU2003256764A1 (en) Point of use lighting controller
AU2003297240A1 (en) Game controller having multiple operation modes
WO2003063892A1 (fr) Utilisation d'apeline
AU2003280669A1 (en) Controller
EP1824739A4 (fr) Regulation du murissement des bananes
AU2003211885A1 (en) Humidity controller
AU2002349553A1 (en) Remote controller
AU2003255287A1 (en) Use of a proteasome inhibitor in the treatment of fibrotic diseases
AU2003226755A1 (en) Carboxylic acid amides
AP2004003163A0 (en) Use of topical compositions for the control of microbial diseases of the nail.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP